__NUXT_JSONP__("/drugs/Crenolanib", (function(a,b){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"670220-88-9",chebiId:"",chemicalFormula:"C26H29N5O2",definition:"An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and\u002For Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.",fdaUniiCode:"LQF7I567TQ",identifier:"C64639",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C1967"],synonyms:["4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-","CP-868,596","CP-868596","CRENOLANIB",a,"PDGFR Inhibitor CP-868596","[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FCrenolanib",extension:".json",createdAt:b,updatedAt:b}}],fetch:{},mutations:void 0}}("Crenolanib","2021-10-30T13:42:32.223Z")));